• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.呼吸道合胞病毒载量、病毒动力学与既往健康自然感染儿童疾病严重程度的关系。
J Infect Dis. 2011 Oct 1;204(7):996-1002. doi: 10.1093/infdis/jir494.
2
Respiratory syncytial virus load predicts disease severity in previously healthy infants.呼吸道合胞病毒载量可预测既往健康婴儿的疾病严重程度。
J Infect Dis. 2005 Jun 1;191(11):1861-8. doi: 10.1086/430008. Epub 2005 Apr 21.
3
Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children.儿童呼吸道合胞病毒亚组、病毒载量与斑块形态及疾病严重程度的关系。
Pediatr Res. 2015 Oct;78(4):380-8. doi: 10.1038/pr.2015.122. Epub 2015 Jun 24.
4
The impact of viral dynamics on the clinical severity of infants with respiratory syncytial virus bronchiolitis.病毒动力学对呼吸道合胞病毒细支气管炎婴儿临床严重程度的影响。
J Med Virol. 2015 Aug;87(8):1276-84. doi: 10.1002/jmv.24111. Epub 2015 Apr 23.
5
Clinical disease and viral load in children infected with respiratory syncytial virus or human metapneumovirus.感染呼吸道合胞病毒或人偏肺病毒的儿童的临床疾病及病毒载量
Diagn Microbiol Infect Dis. 2008 Dec;62(4):382-8. doi: 10.1016/j.diagmicrobio.2008.08.002. Epub 2008 Oct 7.
6
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.莫他珠单抗治疗因呼吸道合胞病毒感染住院的婴儿并不能降低病毒载量或疾病严重程度。
Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240.
7
Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus.评价毛细支气管炎住院婴儿呼吸道合胞病毒载量。
Med Microbiol Immunol. 2012 Aug;201(3):311-7. doi: 10.1007/s00430-012-0233-6. Epub 2012 Mar 10.
8
Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity.住院婴儿呼吸道合胞病毒感染:病毒载量、病毒亚组与疾病严重程度之间的关联
J Med Virol. 2007 Dec;79(12):1951-8. doi: 10.1002/jmv.21026.
9
Viral Load Dynamics and Clinical Disease Severity in Infants With Respiratory Syncytial Virus Infection.呼吸道合胞病毒感染婴儿的病毒载量动态和临床疾病严重程度。
J Infect Dis. 2019 Apr 8;219(8):1207-1215. doi: 10.1093/infdis/jiy655.
10
Association of Viral Load With Disease Severity in Outpatient Children With Respiratory Syncytial Virus Infection.门诊呼吸道合胞病毒感染儿童病毒载量与疾病严重程度的关联
J Infect Dis. 2020 Jun 29;222(2):298-304. doi: 10.1093/infdis/jiaa076.

引用本文的文献

1
Association of 17q12-q21 Asthma Risk Locus with Clinical Severity of Infant Respiratory Syncytial Virus Infection.17q12 - q21哮喘风险基因座与婴儿呼吸道合胞病毒感染临床严重程度的关联
Biomolecules. 2025 Jul 22;15(8):1056. doi: 10.3390/biom15081056.
2
Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention.呼吸道合胞病毒:流行病学、发病机制、诊断、治疗与预防的最新进展及近期研究综述
J Clin Med. 2025 May 30;14(11):3880. doi: 10.3390/jcm14113880.
3
Advances in development of antiviral strategies against respiratory syncytial virus.抗呼吸道合胞病毒抗病毒策略的发展进展
Acta Pharm Sin B. 2025 Apr;15(4):1752-1772. doi: 10.1016/j.apsb.2025.02.015. Epub 2025 Feb 20.
4
Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection.当前针对呼吸道合胞病毒感染的抗病毒疗法及有前景的候选药物。
Virol Sin. 2025 Apr;40(2):147-156. doi: 10.1016/j.virs.2025.01.003. Epub 2025 Jan 28.
5
Impact of Respiratory Syncytial Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection on Clinical Severity and Outcomes Among Children Hospitalized With Lower Respiratory Tract Infections in Soweto, South Africa.呼吸道合胞病毒与严重急性呼吸综合征冠状病毒2合并感染对南非索韦托下呼吸道感染住院儿童临床严重程度及预后的影响
Pediatr Infect Dis J. 2025 Feb 1;44(2):107-111. doi: 10.1097/INF.0000000000004560. Epub 2024 Oct 2.
6
Therapeutic efficacy of JNJ-49214698, an RSV fusion inhibitor, in RSV-infected neonatal lambs.呼吸道合胞病毒融合抑制剂JNJ-49214698对感染呼吸道合胞病毒的新生羔羊的治疗效果。
J Gen Virol. 2024 Dec;105(12). doi: 10.1099/jgv.0.002056.
7
Viral load in hospitalized infants with respiratory syncytial virus bronchiolitis: a three-way comparative analysis.住院婴儿呼吸道合胞病毒毛细支气管炎病毒载量:三项比较分析。
Eur J Pediatr. 2024 Aug;183(8):3471-3478. doi: 10.1007/s00431-024-05614-3. Epub 2024 May 23.
8
Bronchiolitis recovery and the use of High Efficiency Particulate Air (HEPA) Filters (The BREATHE Study): study protocol for a multi-center, parallel, double-blind, randomized controlled clinical trial.毛细支气管炎康复和高效空气过滤器(HEPA)的使用(BREATHE 研究):一项多中心、平行、双盲、随机对照临床试验的研究方案。
Trials. 2024 Mar 20;25(1):197. doi: 10.1186/s13063-024-08012-0.
9
Liposomal Glutathione Augments Immune Defenses against Respiratory Syncytial Virus in Neonatal Mice Exposed in Utero to Ethanol.脂质体谷胱甘肽增强子宫内暴露于乙醇的新生小鼠对呼吸道合胞病毒的免疫防御。
Antioxidants (Basel). 2024 Jan 23;13(2):137. doi: 10.3390/antiox13020137.
10
Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus.重塑我们的认知:在理解人类呼吸道合胞病毒免疫反应方面取得的进展
Pathogens. 2023 Sep 1;12(9):1118. doi: 10.3390/pathogens12091118.

本文引用的文献

1
Viral load drives disease in humans experimentally infected with respiratory syncytial virus.病毒载量驱动人类呼吸道合胞病毒感染实验中的疾病。
Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14. doi: 10.1164/rccm.201002-0221OC. Epub 2010 Jul 9.
2
Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population.表面活性蛋白 A2 多态性与呼吸道合胞病毒感染人群疾病严重程度的关系。
J Pediatr. 2010 Mar;156(3):409-14. doi: 10.1016/j.jpeds.2009.09.043. Epub 2009 Nov 14.
3
Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.呼吸道合胞病毒细支气管炎的遗传易感性主要与先天免疫基因相关。
J Infect Dis. 2007 Sep 15;196(6):826-34. doi: 10.1086/520886. Epub 2007 Aug 10.
4
Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus.实时逆转录聚合酶链反应检测法与培养技术在定量评估自然感染呼吸道合胞病毒儿童病毒载量中的比较
J Clin Microbiol. 2005 May;43(5):2356-62. doi: 10.1128/JCM.43.5.2356-2362.2005.
5
Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load.婴儿呼吸道合胞病毒A和B亚组的自然感染:频率、疾病严重程度和病毒载量的研究
Pediatr Res. 2004 Dec;56(6):914-7. doi: 10.1203/01.PDR.0000145255.86117.6A. Epub 2004 Oct 6.
6
Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.呼吸道合胞病毒可诱发小鼠肺炎、细胞因子反应、气道阻塞以及与长期气道高反应性相关的慢性炎性浸润。
J Infect Dis. 2004 May 15;189(10):1856-65. doi: 10.1086/386372. Epub 2004 Apr 29.
7
Latency and persistence of respiratory syncytial virus despite T cell immunity.尽管存在T细胞免疫,呼吸道合胞病毒仍具有潜伏性和持续性。
Am J Respir Crit Care Med. 2004 Apr 1;169(7):801-5. doi: 10.1164/rccm.200308-1203OC. Epub 2004 Jan 23.
8
Case fatality proportions and predictive factors for mortality among children hospitalized with severe pneumonia in a rural developing country setting.在一个农村发展中国家环境中,因重症肺炎住院儿童的病死率及死亡预测因素。
J Trop Pediatr. 2003 Dec;49(6):327-32. doi: 10.1093/tropej/49.6.327.
9
Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis.白细胞介素-10、白细胞介素-9和肿瘤坏死因子-α基因启动子变异对呼吸道合胞病毒细支气管炎的影响。
J Infect Dis. 2004 Jan 15;189(2):239-47. doi: 10.1086/380908. Epub 2004 Jan 9.
10
Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease.呼吸道合胞病毒下呼吸道疾病的环境和人口统计学风险因素。
J Pediatr. 2003 Nov;143(5 Suppl):S118-26. doi: 10.1067/s0022-3476(03)00511-0.

呼吸道合胞病毒载量、病毒动力学与既往健康自然感染儿童疾病严重程度的关系。

Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

机构信息

Division of Pediatric Infectious Diseases, Department of Pediatrics, Harvard Medical School, Massachusetts General Hospital for Children, Boston, USA.

出版信息

J Infect Dis. 2011 Oct 1;204(7):996-1002. doi: 10.1093/infdis/jir494.

DOI:10.1093/infdis/jir494
PMID:21881113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3203391/
Abstract

BACKGROUND

Respiratory syncytial virus (RSV) disease severity was thought to be a result of host immunopathology but alternatively may be driven by high-level viral replication. The relationships between RSV load, viral clearance dynamics, and disease severity have not been carefully evaluated.

METHODS

Previously healthy RSV-infected children <2 years old were recruited. RSV load was measured in respiratory secretions by fresh quantitative culture over 3 hospital days. Measures of disease severity were hospital admission, duration of hospitalization, requirement for intensive care, and respiratory failure.

RESULTS

Multivariate logistic regression models revealed independent predictors of increased duration of hospitalization: male sex, lower weight, and higher viral load on any day. Viral loads at day 3 were more significantly associated with requirement for intensive care and respiratory failure than were viral loads at earlier time points. Faster RSV clearance was independently associated with shorter hospitalization.

DISCUSSION

These observations challenge the immunopathology-based pathogenesis paradigm. They also have major therapeutic implications, suggesting that application of antiviral agents early in the disease course, even at a time when viral replication is at its highest, might improve subsequent morbidity by significantly lowering viral load and direct viral cytopathic effects, and aborting the potential downstream immunopathology.

摘要

背景

呼吸道合胞病毒 (RSV) 疾病的严重程度被认为是宿主免疫病理学的结果,但也可能是由高水平的病毒复制驱动的。RSV 载量、病毒清除动力学与疾病严重程度之间的关系尚未得到仔细评估。

方法

招募了年龄 <2 岁的先前健康的 RSV 感染儿童。通过新鲜定量培养在 3 个住院日期间测量呼吸道分泌物中的 RSV 载量。疾病严重程度的衡量标准为住院、住院时间、需要重症监护和呼吸衰竭。

结果

多变量逻辑回归模型显示住院时间延长的独立预测因素:男性、体重较低和任何一天的病毒载量较高。第 3 天的病毒载量与需要重症监护和呼吸衰竭的相关性比早期时间点的病毒载量更为显著。RSV 清除速度较快与住院时间缩短独立相关。

讨论

这些观察结果挑战了基于免疫病理学的发病机制范式。它们还具有重要的治疗意义,表明即使在病毒复制达到最高水平时,在疾病早期应用抗病毒药物也可能通过显著降低病毒载量和直接病毒细胞病变作用,并阻断潜在的下游免疫病理学,从而改善随后的发病率。